Abstracts tagged "Anti-TNF Drugs"

Abstract Number: 0239 • ACR Convergence 2024
Neutralising Antibody Responses to Bivalent SARS-CoV-2 Vaccines and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study
Hilde S. Ørbo¹, Taissa M. Kasahara², Asia-Sophia Wolf³, Kristin H. Bjørlykke⁴, Joseph Sexton⁵, Ingrid Jyssum⁵, Anne Therese Tveter⁵, Guri Solum³, Ingrid Fadum Kjønstad³, Andreas Lind⁶, Veselka Petrova Dimova-Svetoslavova⁶, Tore K. Kvien⁷, Jørgen Jahnsen⁸, Espen A. Haavardsholm¹, Ludvig A. Munthe⁹, Sella A. Provan⁵, John Torgils Vaage⁹, Siri Mjaaland³, Kristin K. Jørgensen⁴, Gunnveig Grødeland⁹, Silje W. Syversen¹⁰ and Guro L. Goll¹⁰, ¹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ²University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ³Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, ⁴Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Oslo University Hospital, Department of Microbiology, Oslo, Norway, Oslo, Norway, ⁷Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁸Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, ⁹Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway
Background/Purpose: The SARS-CoV-2 virus mutates continuously, posing challenges for patients with immune-mediated inflammatory diseases (IMIDs) on tumour necrosis factor inhibitors (TNFi). These patients often have…
Abstract Number: 1015 • ACR Convergence 2024
Performance of a Molecular Signal Response Classifier Predicting Inadequate Response to Tumor Necrosis Factor Inhibitors in Hispanic Patients with Rheumatoid Arthritis
Viet Bui¹, Miguel Rodriguez² and Sarah Ormseth³, ¹Harbor UCLA Medical Center and The Lundquist Institute, Torrance, CA, ²Texas Arthritis Center, El Paso, TX, ³The Lundquist Institute, Torrance, CA
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
Abstract Number: 2338 • ACR Convergence 2024
TNF Inhibitor Therapy Increases Absolute Lymphocyte Count Which Is Associated with Lower Mortality in Patients with Psoriatic Arthritis
Lenche Kostadinova¹, Brigid Wilson², Hinnah Siddiqui², Sara Behrens³, Angela Gupta⁴, Megan O'Mara³, Vicky Nahra⁵, Mahesha Makandura⁶, Shahdi Malakooti⁷, Maya Mattar⁸, David A Zidar¹ and Donald D Anthony⁹, ¹Louis Stokes VA Medical Center, cleveland, ²VA Northeast Ohio Healthcare System, Cleveland, ³CWRU, Cleveland, ⁴Brigham and Women's Faulkner Hospital, Rheumatology Center, Jamaica Plain, ⁵University Hospitals Cleveland Medical Center, Cleveland, ⁶Henri Ford Medical Center, Detroit, ⁷MetroHealth at Case Western Reserve University, Cleveland, ⁸Louis Stokes VA medical Center, Mayfield Heights, OH, ⁹Louis Stokes VA Medical Center/Metro Health, Cleveland
Background/Purpose: Pathogenic inflammation in psoriatic arthritis (PsA) includes TNF pathway engagement, and this is associated with morbidity. Recently, we observed lower absolute lymphocyte count (ALC)…
Abstract Number: 0240 • ACR Convergence 2024
Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study
Hilde S. Ørbo¹, Asia-Sophia Wolf², Taissa M. Kasahara³, Kristin H. Bjørlykke⁴, Ingrid Jyssum⁵, Joseph Sexton⁵, Anne Therese Tveter⁵, Guri Solum², Ingrid Fadum Kjønstad², Ingrid E. Christensen⁵, Tore K. Kvien⁶, Jørgen Jahnsen⁷, Espen A. Haavardsholm¹, Ludvig A. Munthe⁸, Sella A. Provan⁵, John Torgils Vaage⁸, Kristin K. Jørgensen⁴, Gunnveig Grødeland⁸, Siri Mjaaland², Silje W. Syversen⁹ and Guro L. Goll⁹, ¹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ²Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, ³University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁴Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁷Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, ⁸Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated humoral vaccine responses and are prone to more severe infections. Assessing the persistence…
Abstract Number: 1037 • ACR Convergence 2024
Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review
Alice Terrett¹, Athena Chin², Mihye Kwon³, Samuel Whittle⁴ and Catherine Hill⁵, ¹The Queen Elizabeth Hospital, Adelaide, Australia, ²Royal Adelaide Hospital, Tranmere, South Australia, Australia, ³Konyang University, College of Medicine, Daejeon, Republic of Korea, ⁴The Queen Elizabeth Hospital, Springfield, South Australia, Australia, ⁵The Queen Elizabeth Hospital, Woodville, South Australia, Australia
Background/Purpose: The use of disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of autoimmune rheumatic diseases, including rheumatoid arthritis (RA), has significantly improved disease and functional…
Abstract Number: 2347 • ACR Convergence 2024
Drug Survival in Spondyloarthritis: Anti-IL17 Outperforms Anti-TNF in First Biologic Treatment
Thao Pham¹, Raphaëlle Curmin², BENOIT FLACHAIRE³, Florence Tubach² and Corinne MICELI⁴, ¹Assistance Publique-Hôpitaux de Marseille, Marseille, France, ²Cephepi, Sorbonne Université, INSERM, APHP, Paris, Paris, France, ³Aix Marseille University, Marseille, France, ⁴Université de Paris Cité, APHP, Paris, France
Background/Purpose: Drug survival rates serve as key indicators for assessing both the efficacy and safety of treatments in real life setting. Our aim was to…
Abstract Number: 0256 • ACR Convergence 2024
Anti-TNF Therapy as a Potential Risk of Leishmania Infections
Gloria Albaladejo Paredes¹, Alicia Pérez González¹, Esther Monleón Acosta¹, Jose Andrés Rodríguez Fernández¹, Pedro José Manuel Hernández¹, Carlos Fernández Díaz¹, María Rosario Oliva Ruíz¹, Jose María Andreu Ubero², Paloma Valentina Castillo Dayer², Edgar Soriano Navarro³, David Pérez Parra⁴, Claudia Alejandra Capozzi², María Rocío González Molina⁵, José Francisco Orts Paco⁶, José Pablo Serrano Serra⁶ and Vicente Cogolludo Campillo², ¹Hospital Universitario Santa Lucía, CARTAGENA, Spain, ²Hospital Universitario Santa Lucía, Cartagena, Murcia, Spain, ³Hospital Universitario Santa Lucía, Murcia, Murcia, Spain, ⁴Hospital Universitario Santa Lucía, Murcia, ⁵Hospital Reina Sofía, Murcia, Murcia, Spain, ⁶Hospital Universitario Reina Sofía, Murcia, Murcia, Spain
Background/Purpose: Leishmaniasis is an infectious disease caused by protozoon that occurs endemically in the Mediterranean Basin and South America and can affects to travellers to…
Abstract Number: 1377 • ACR Convergence 2024
Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases
Adrián Quevedo-Rodríguez¹, Lucia Otero-Varela², Fernando Sánchez-Alonso³, Yanira Pérez-Vera¹, Javier Manero-Ruiz⁴, Cristina Campos-Fernández⁵, Sara Manrique-Arija⁶, Paloma Vela-Casasempere⁷, Antonio Mera-Varela⁸, César Díaz⁹, Atusa Movasat¹⁰, Blanca Garcia-Magallon¹¹, Inmaculada Ros-Vilamajó¹², Carolina Perez-Garcia¹³ and Isabel Castrejon¹⁴, and BIOBADASER working group., ¹Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁵Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ⁶Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, ⁷Hospital General Universitario Alicante, Alicante, Spain, ⁸Department of Rheumatology. Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Universitario Príncipe de Asturias, Madrid, Spain, ¹¹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ¹²Hospital Universitari Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain, ¹³Hospital del Mar, Barcelona, Spain, ¹⁴Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain
Background/Purpose: Biologic and targeted synthetic disease-modifying drugs (b/tsDMARDs) have changed the way rheumatoid arthritis (RA) is managed in recent years. Still, some patients remain symptomatic…
Abstract Number: 2359 • ACR Convergence 2024
A Real-World Study on the Clinical Characteristics and Patient Reported Outcomes of Patients with Active AxSpA Prescribed CT-P13 SC in Five European Countries
Xenofon Baraliakos¹, Ye Eun Lee², Soyeon Park², Young Nam Lee², Megan Hughes³, Molly Edwards³, Emily Quiñones⁴ and Raj Sengupta⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Celltrion, Inc., Incheon, Republic of Korea, ³Adelphi Real World, Bollington, United Kingdom, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: CT-P13 SC, a new formulation of infliximab administered subcutaneously, has been approved by European Medicine Agency for the treatment of radiographic axial spondylarthritis (axSpA)…
Abstract Number: 0291 • ACR Convergence 2024
Safety of Biologic Therapy in Kidney Transplant Recipients with Inflammatory Diseases: Real-world Experience from a Tertiary Medical Center
Victoria Furer¹, Omer Kersh², Mark Berman³, Ayelet Grupper² and Ori Elkayam⁴, ¹Tel Aviv Medical Center, Tel Aviv, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Tel Aviv, Israel, ³Tel Aviv Sourasky Medical Center, Kefar sava, Israel, ⁴Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Management of solid-organ transplant (SOT) recipients with systemic inflammatory diseases represents a clinical challenge in the paucity of data related to the safety of…
Abstract Number: 1401 • ACR Convergence 2024
Risk of Malignancy with TNF-α Inhibitors in Patients with Rheumatoid Arthritis
Omair Khan¹, Syed Mujtaba Baqir², Azka Naeem², Muhammad Hashim khan², Tharun Shyam², Kseniya Slobodyanyuk³ and Anastasia Slobodnick⁴, ¹Maimonides Medical Center, Council Bluffs, IA, ²Maimonides Medical Center, Brooklyn, NY, ³Maimonides Medical Center, Manhattan, NY, ⁴Northwell, Staten Island, NY
Background/Purpose: Rheumatoid arthritis (RA) is associated with various comorbidities and complications among which cancer has been highlighted in literature. This cancer risk has been attributed…
Abstract Number: 2598 • ACR Convergence 2024
p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines
Zhihua Ma, Luis Carvajal, Andrew Chen, Rosa Villagomez, Yare calderon, Tamara Hopkins, Hua Gao, Benjamin Trotter, Charles Lin and Peter Rahl, Kronos Bio, Cambridge, MA
Background/Purpose: Across inflammatory and autoimmune diseases, pathologic signaling converges in the nucleus to elevate transcription of numerous inflammatory effectors such as cytokines, chemokines and antibodies.…
Abstract Number: 0356 • ACR Convergence 2024
Patient Satisfaction and Experience After a Switch to a Citrate-free High-concentration Adalimumab Biosimilar. Results from a Prospective Multicentric Real-world Study
Hubert Marotte¹, Laure Gossec², Vered ABITBOL³, Eric SENBEL⁴, Guillaume BONNAUD⁵, Xavier ROBLIN⁶, Yoram BOUHNIK⁷, Stéphane NANCEY⁸, Nicolas MATHIEU⁹, jérôme FILIPPI¹⁰, Lucine VUITTON¹¹, Stéphane NAHON¹², Azeddine Dellal¹², Alice DENIS¹³, Caroline HABAUZIT¹³, Salim BENKHALIFA¹³ and Guillaume BOUGUEN¹⁴, ¹Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, ²Sorbonne Université, Paris, France, ³Cochin University Hospital, Paris, France, ⁴Medical practice, Marseille, Marseille, France, ⁵Ambroise Paré Clinic, Toulouse, France, ⁶Saint-Etienne University Hospital, Saint-Etienne, France, ⁷Institut des MICI, Paris IBD Center, Neuilly-Sur-Seine, France, ⁸Hospices Civils de Lyon, Lyon, France, ⁹Clinic of Cèdres, Echirolles, France, ¹⁰Saint-Jean Clinic, Cagnes sur Mer, France, ¹¹Besançon university hospital, Besançon, France, ¹²Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France, ¹³Celltrion Healthcare France, Issy Les Moulineaux, France, ¹⁴Rennes University Hospital, Rennes, France
Background/Purpose: Biosimilars (BioS) are cost-effective alternatives to reference products for patients with chronic inflammatory rheumatic diseases (CIRD) and inflammatory bowel diseases (IBD), but treatment adherence…
Abstract Number: 1452 • ACR Convergence 2024
Assessing Responsiveness of Outcome Measures for Children with Axial Juvenile Spondyloarthritis (JSpA)
Timothy Brandon¹, Rui Xiao², Cassandra Muir¹, Matthew Stoll³, Daniel Lovell⁴, Edward Oberle⁵, Nancy Chauvin⁶, Michael Francavilla⁷, Walter Maksymowych⁸ and Pamela Weiss⁹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶The Imaging Institute @ The Cleveland Clinic, Cleveland, OH, ⁷Department of Radiology, Whiddon College of Medicine, University of South Alabama, Mobile, AL, ⁸University of Alberta, Edmonton, AB, Canada, ⁹Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Trials for patients with juvenile spondyloarthritis (JSpA) and axial disease are scarce. We assessed the responsiveness of measures for use in trials of patients…
Abstract Number: 2619 • ACR Convergence 2024
Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients
Tali Eviatar¹, Iftach Sagy², Elad Brav², Amir Bieber³, Victoria Furer⁴ and Ori Elkayam⁵, ¹Tel Aviv Medical Center, Ramat Gan, HaMerkaz, Israel, ²Soroka Medical Cenrter, beer sheva, Israel, ³Emek Medical Center, Clalit Health Services, Raanana, Israel, ⁴Tel Aviv Medical Center, Tel Aviv, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Patients treated with biologic or targeted synthetic (b/ts) DMARDs are recommended to perform safety blood monitoring every 3 months in the absence of strong…

1
2
3
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].